Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection

AIM: To evaluate new therapies for hepatitis C virus (HCV), data about real-world outcomes are needed. METHODS: Outcomes of 223 patients with genotype 1 HCV who started telaprevir- or boceprevir-based triple therapy (May 2011-March 2012) at the Mount Sinai Medical Center were analyzed. Human immunod...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:World J Hepatol
Päätekijät: Bichoupan, Kian, Tandon, Neeta, Martel-Laferriere, Valerie, Patel, Neal M, Sachs, David, Ng, Michel, Schonfeld, Emily A, Pappas, Alexis, Crismale, James, Stivala, Alicia, Khaitova, Viktoriya, Gardenier, Donald, Linderman, Michael, Olson, William, Perumalswami, Ponni V, Schiano, Thomas D, Odin, Joseph A, Liu, Lawrence U, Dieterich, Douglas T, Branch, Andrea D
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Baishideng Publishing Group Inc 2017
Aiheet:
Observational Study
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5395804/
https://ncbi.nlm.nih.gov/pubmed/28469811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v9.i11.551
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia